A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) has identified a promising drug combination for the treatment of muscle-invasive bladder cancer. Rosiglitazone plus trametinib worked synergistically to not only induce tumor cell death, but also shift aggressive tumor cells to a more benign molecular subtype.
Promising drug combo targets aggressive bladder cancers
